EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Clinical performance of Abbott ID NOW™ COVID-19 2.0 rapid molecular point-of-care test compared to three real-time RT-PCR assays

Maria D Iglesias-Ussel iD, Aleah Bowie, Jack G Anderson, Yin Li, Lawrence P Park, Jose F Cardona, Patrick Dennis, Valentine Ebuh, Steven A Geller, Manish Jain, Mark M McKenzie, Kian Merchant-Borna und 6 weitere

Microbiology Spectrum · 2025

DOI: 10.1128/spectrum.02033-24 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Maria D Iglesias-Ussel und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, Point-of-Care Testing, COVID-19 Nucleic Acid Testing. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Timely diagnosis of SARS-CoV-2 is important for infection control and treatment. Real-time reverse transcriptase PCR (rRT-PCR) tests are the reference standard for diagnosis but often require a centralized laboratory, making them time-intensive and unsuitable for resource-limited settings. The Abbott ID NOW™ COVID-19 2.0 assay is a rapid point-of-care (POC), isothermal molecular test for qualitative detection of SARS-CoV-2. We prospectively evaluated its clinical performance against three reference rRT-PCR tests: Hologic Panther Fusion, Roche Cobas, and CDC 2019-nCoV RT-PCR Diagnostic Panel. Investigators enrolled 3,530 subjects, with 3,146 evaluable. In symptomatic subjects ( n = 914), the test showed a positive percent agreement (PPA) of 91.7% (95% confidence interval [CI]: 87.8, 94.4) and a negative percent agreement (NPA) of 98.4% (95% CI: 97.1, 99.1). The PPA improved with lower cycle threshold (Ct) values: 94.7% (95% CI: 91.2, 97.2) for Ct ≤36, 97.6% (95% CI: 94.5, 99.2) for Ct ≤33, and 99.4% (95% CI: 96.8, 100.0) for Ct ≤30. Discordant results were observed among the three reference rRT-PCR tests across evaluable subjects with suspected COVID-19 infection. For 1,630 cases of symptomatic and asymptomatic subjects suspected of COVID-19, where all three rRT-PCR methods were evaluable, CDC test results differed the most, with 144 discordant results with Roche and 119 with Panther rRT-PCR tests. Roche and Panther test results differed in 67 cases. In summary, the Abbott ID NOW™ COVID-19 2.0 assay can serve as a valuable diagnostic tool in acute symptomatic subjects in point-of-care settings. IMPORTANCE The Abbott ID NOW TM COVID-19 2.0 assay is a suitable rapid test for diagnosing COVID-19 in acute symptomatic subjects and can be used in point-of-care settings and low-resource settings. With results reported in 12 minutes or less, Abbott ID NOW TM COVID-19 2.0 facilitates timely diagnosis, enabling linkage to appropriate antiviral medication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19SARS-CoV-2Point-of-Care TestingCOVID-19 Nucleic Acid TestingReal-Time Polymerase Chain ReactionMolecular Diagnostic TechniquesHumansMaleMiddle AgedFemaleAdultProspective StudiesSensitivity and SpecificityAgedPoint-of-Care SystemsYoung AdultAdolescentCOVID-19 TestingAged, 80 and overChild

Stichwörter der Autor:innen

COVID-19ID NOWPOCSARS-CoV-2isothermalnicking endonuclease amplification reaction (NEAR)rRT-PCRrapid testing

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
  • Abbott Rapid Diagnostics, a Division of Abbott Laboratories, San Diego, California, USA.
  • Duke Global Health Institute, Duke University, Durham, North Carolina, USA.
  • Indago Research and Health Center Inc, Hialeah, Florida, USA.
  • DelRicht Research, New Orleans, Louisiana, USA.
  • Global Medical Research LLC, Dallas, Texas, USA.

ORCID-Profile: Maria D Iglesias-Ussel

Zitieren

APA

Iglesias-Ussel, M. D., Bowie, A., Anderson, J. G., Li, Y., Park, L. P., Cardona, J. F., Dennis, P., Ebuh, V., Geller, S. A., Jain, M., McKenzie, M. M., Merchant-Borna, K., Patel, A., Siegel, A., Strauss, G. S., Thoppil, J. J., Weinberg, A. S., & Woods, C. W. (2025). Clinical performance of Abbott ID NOW™ COVID-19 2.0 rapid molecular point-of-care test compared to three real-time RT-PCR assays. Microbiology Spectrum. https://doi.org/10.1128/spectrum.02033-24

Vancouver

Iglesias-Ussel MD, Bowie A, Anderson JG, Li Y, Park LP, Cardona JF, et al. Clinical performance of Abbott ID NOW™ COVID-19 2.0 rapid molecular point-of-care test compared to three real-time RT-PCR assays. Microbiology Spectrum. 2025. doi:10.1128/spectrum.02033-24

BibTeX
@article{IglesiasUssel2025,
  author = {Iglesias-Ussel, Maria D and Bowie, Aleah and Anderson, Jack G and Li, Yin and Park, Lawrence P and Cardona, Jose F and Dennis, Patrick and Ebuh, Valentine and Geller, Steven A and Jain, Manish and McKenzie, Mark M and Merchant-Borna, Kian and Patel, Anand and Siegel, Amy and Strauss, Guy S and Thoppil, Joby J and Weinberg, Aaron S and Woods, Christopher W},
  title = {Clinical performance of Abbott ID NOW™ COVID-19 2.0 rapid molecular point-of-care test compared to three real-time RT-PCR assays},
  journal = {Microbiology Spectrum},
  year = {2025},
  doi = {10.1128/spectrum.02033-24}
}
Kostenlos starten →